Medifoxamine
From Wikipedia, the free encyclopedia
Medifoxamine
|
|
Systematic (IUPAC) name | |
N,N-dimethyl-2,2-bis(phenoxy)ethanamine | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C16H19NO2 |
Mol. mass | 257.328 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Medifoxamine is an antidepressant drug which inhibits the reuptake of dopamine[1] and acts as an agonist at the 5HT2A and 5HT2C receptors.[2] It was used mainly in France,[3] but was withdrawn following problems with hepatotoxicity.[4]
[edit] References
- ^ Saleh S, Turner P. Ocular hypotensive effects of medifoxamine. British Journal of Clinical Pharmacology. 1992 Sep;34(3):269-71. PMID 1389953
- ^ Martin P, Lemonnier F. The role of type 2 serotonin receptors, 5-HT2A and 5-HT2C, in depressive disorders: effect of medifoxamine. (French) L'Encéphale. 1994 Jul-Aug;20(4):427-35. PMID 7988407
- ^ Mitchell PB. Novel French antidepressants not available in the United States. Psychopharmacology Bulletin. 1995;31(3):509-19. PMID 8668756
- ^ Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D. Hepatic tolerance of atypical antipsychotic drugs. (French). L'Encéphale. 2002 Nov-Dec;28(6 Pt 1):542-51. PMID 12506267
|